Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SBLOF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.4 Med: 0.44 Max: 0.52
Current: 0.41
During the past 13 years, the highest Equity to Asset Ratio of Shin Nippon Biomedical Laboratories was 0.52. The lowest was 0.40. And the median was 0.44.
SBLOF's Equity-to-Asset is ranked worse than 72.51% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs SBLOF: 0.41
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Shin Nippon Biomedical Laboratories Equity-to-Asset Related Terms
Shin Nippon Biomedical Laboratories Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBLOF vs TMO, DHR, IDXX: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shin Nippon Biomedical Laboratories Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Shin Nippon Biomedical Laboratories's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shin Nippon Biomedical Laboratories (SBLOF) has a Equity-to-Asset of 0.41 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shin Nippon Biomedical Laboratories and its competitors. This is near median its historical median of 0.44. Over the past decade, Shin Nippon Biomedical Laboratories' Equity-to-Asset has ranged from 0.40 to 0.52. According to the industry distribution chart, Shin Nippon Biomedical Laboratories ranks #153 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 72.5%.
Is Shin Nippon Biomedical Laboratories' Equity-to-Asset too high?
Shin Nippon Biomedical Laboratories' current Equity-to-Asset of 0.41 is near median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 0.52. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Shin Nippon Biomedical Laboratories' value of 0.41 is 30.5% below this industry median. Based on the distribution chart, Shin Nippon Biomedical Laboratories ranks #153 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shin Nippon Biomedical Laboratories has a GF Scoreâ„¢ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Shin Nippon Biomedical Laboratories' Equity-to-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shin Nippon Biomedical Laboratories ranks #153 out of 211 companies for Equity-to-Asset. This places Shin Nippon Biomedical Laboratories in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Shin Nippon Biomedical Laboratories' value of 0.41 is 30.5% below this benchmark. Historically, Shin Nippon Biomedical Laboratories' own Equity-to-Asset has ranged from 0.40 to 0.52 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.59, Shin Nippon Biomedical Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shin Nippon Biomedical Laboratories's current Equity-to-Asset of 0.41 is 30.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Shin Nippon Biomedical Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shin Nippon Biomedical Laboratories's current Equity-to-Asset is 0.41, which is near median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shin Nippon Biomedical Laboratories stock overvalued right now?
Shin Nippon Biomedical Laboratories (SBLOF) has a current Equity-to-Asset of 0.41. The stock's GF Value™ is $12.83, compared to a current price of $9.16 — trading 28.6% below its estimated fair value. The current Equity-to-Asset is 0.41, which is near median its 10-year median of 0.44 and 30.5% below the Medical Diagnostics & Research industry median of 0.59. Shin Nippon Biomedical Laboratories' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Shin Nippon Biomedical Laboratories (SBLOF), the current Equity-to-Asset is 0.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued.
The current stock price of $9.16 is trading 28.6% below its estimated GF Value™ of $12.83.
Key valuation signals for SBLOF:
Equity-to-Asset: 0.41 (near median its 10-year median of 0.44)
GF Value™: $12.83 vs. price of $9.16 (28.6% below fair value)
Industry Position: 30.5% below the Medical Diagnostics & Research median (#153 of 211)
No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shin Nippon Biomedical Laboratories Business Description
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
76GF Score
Get the complete analysis for SBLOF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBLOF has been successfully added to your 
